Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Next Science Ltd ( (AU:NXS) ) has provided an announcement.
Next Science Limited has announced a General Meeting scheduled for August 28, 2025, to discuss the proposed asset purchase agreement with Demetra, which involves the sale of Next Science’s main undertaking. This transaction requires shareholder approval as per Listing Rule 11.2, and the meeting will be conducted both in-person and virtually. The outcome of this meeting could significantly impact the company’s operations and market positioning, as it involves a major asset sale.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science is a medical technology company based in Sydney, Australia, with a research and development center in Jacksonville, Florida, USA. Founded in 2012, the company focuses on developing and commercializing its proprietary XBIO™ technology aimed at reducing the impact of infections in human health.
YTD Price Performance: 21.74%
Average Trading Volume: 475,424
Technical Sentiment Signal: Sell
Current Market Cap: A$40.97M
See more insights into NXS stock on TipRanks’ Stock Analysis page.